What is Fulgent Genetics, Inc.'s therapeutic development — D&A?

Fulgent Genetics, Inc. (FLGT) reported therapeutic development — D&A of $143K in Q1 2026.

How has Fulgent Genetics, Inc.'s therapeutic development — D&A changed year-over-year?

Fulgent Genetics, Inc.'s therapeutic development — D&A decreased by 12.8% year-over-year, from $164K to $143K.

What does therapeutic development — D&A mean?

This reflects the non-cash expense allocated to the therapeutic development segment for the systematic allocation of the cost of tangible and intangible assets over their useful lives. It is essential for understanding the capital intensity and asset consumption of the segment.

Fulgent Genetics, Inc. FLGT Therapeutic Development — D&A

Other segment segments

Laboratory Services

$5.86M+1.8%

Similar metrics at other companies

DUOTTechnologies — D&A

$101.89K-38.0%

CCThermal And Specialized Solutions — D&A

$18M+12.5%

ASSTMedical Device — D&A

$32K—

AMP

AMPHPharmaceutical Products — D&A

$14.35M+5.4%

ABMTechnical Solutions — D&A

$2.6M+35.1%

OPKDiagnostics — D&A

$3.93M-31.1%

Other financials

Income statement

See full

Revenue$71.1M-3.2%

Gross profit$21.5M-24.2%

Operating income-$34.6M-74.9%

Net income-$24.8M-115%

EPS (diluted)-$0.80-116%

Balance sheet

See full

Cash & equivalents$23.4M-65.2%

Total debt$8.2M+40.5%

Total equity$1.0B-6.9%

Total assets$1.2B-4.1%

Cash flow

See full

Operating cash flow$7.1M+260%

CapEx$5.2M+10.3%

Free cash flow$1.9M+121%

Valuation

See full

Market cap$552.11M-7.1%

Enterprise value$536.92M+0.7%

P/S1.7×-0.3×

Profitability

See full

Gross margin38.7%-0.1pp

Operating margin-33.1%+17.4pp

Net margin-23%+43.3pp

FCF margin-36.9%—

Returns & leverage

See full

Return on equity-6.8%+48.2pp

Debt / equity0×0.0×

Current ratio5.3×-1.0×

Where this comes from

Reported directly by Fulgent Genetics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Fulgent Genetics, Inc.'s therapeutic development — d&a.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Fulgent Genetics, Inc.'s therapeutic development — D&A?: Fulgent Genetics, Inc. (FLGT) reported therapeutic development — D&A of $143K in Q1 2026.
How has Fulgent Genetics, Inc.'s therapeutic development — D&A changed year-over-year?: Fulgent Genetics, Inc.'s therapeutic development — D&A decreased by 12.8% year-over-year, from $164K to $143K.
What does therapeutic development — D&A mean?: This reflects the non-cash expense allocated to the therapeutic development segment for the systematic allocation of the cost of tangible and intangible assets over their useful lives. It is essential for understanding the capital intensity and asset consumption of the segment.